Highest-materiality recent filing
BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics
Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.
Chemrex board streamlined to two directors: Matthew L. Barsing (Chairman) and Angeline Chong (Director, BioNexus CFO).
BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests
Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.
BioNexus Gene Lab Corp. shareholders elect all four director nominees and approve 2025 equity plan
Directors re-elected: Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, Chee Keong Yap.
Chemrex subsidiary governance shake-up: four directors resign; new chairman appointed
Four Chemrex officers/directors (Too Kam Tham, Liong Tai Tan, Wei Foong Lim, Kuan Yew Tan) resigned on Dec 19, 2025.
ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.
BioNexus files $100M shelf, enters $20M ATM with Maxim Group
Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $20M of common stock via ATM.
BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia
BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia
BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.
BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia
BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.
BioNexus Gene Lab appoints Chong Set Fui as CFO effective immediately
Appointed Chong Set Fui (Angeline) as CFO and Principal Financial Officer, effective June 17, 2025.
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.
Max materiality 0.75 · Median 0.50 · Most common event other_material